Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Lars Akslen

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Immunohistochemistry

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Klingen Tor Audun; Klaasen Herman; Aas Hans; Chen Ying; Akslen Lars A
Secondary breast cancer: a 5-year population-based study with review of the literature.
Engelsen Ingeborg B; Akslen Lars A; Salvesen Helga B
Biologic markers in endometrial cancer treatment.
Fluge Ø; Gravdal K; Carlsen E; Vonen B; Kjellevold K; Refsum S; Lilleng R; Eide T J; Halvorsen T B; Tveit K M; Otte A P; Akslen L A; Dahl O;
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Lars Akslen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Klingen Tor Audun; Klaasen Herman; Aas Hans; Chen Ying; Akslen Lars A
Secondary breast cancer: a 5-year population-based study with review of the literature.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2009;117(10):762-7.
2009: Engelsen Ingeborg B; Akslen Lars A; Salvesen Helga B
Biologic markers in endometrial cancer treatment.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2009;117(10):693-707.
2009: Fluge Ø; Gravdal K; Carlsen E; Vonen B; Kjellevold K; Refsum S; Lilleng R; Eide T J; Halvorsen T B; Tveit K M; Otte A P; Akslen L A; Dahl O;
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis.
British journal of cancer 2009;101(8):1282-9.
2009: Maehle Bjørn O; Collett Karin; Tretli Steinar; Akslen Lars A; Grotmol Tom
Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2009;117(9):644-50.
2009: Ni Bhriain Hannah; Trovik Jone; Wik Elisabeth; Stefansson Ingunn M; Akslen Lars A; Salvesen Helga B; Staff Anne Cathrine
Plasma calprotectin concentrations in women with endometrial carcinoma.
Gynecologic oncology 2009;114(3):491-5.
2009: Rostad Kari; Hellwinkel Olaf J C; Haukaas Svein A; Halvorsen Ole J; Øyan Anne M; Haese Alexander; Budäus Lars; Albrecht Heiko; Akslen Lars A; Schlomm Thorsten; Kalland Karl-Henning
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2009;117(8):575-82.
2009: Kang Soo-Young; Halvorsen Ole J; Gravdal Karsten; Bhattacharya Nandita; Lee Jung Min; Liu Nathan W; Johnston Brian T; Johnston Adam B; Haukaas Svein A; Aamodt Kristie; Yoo Sun; Akslen Lars A; Watnick Randolph S
Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(29):12115-20.
2009: Gravdal Karsten; Halvorsen Ole J; Haukaas Svein A; Akslen Lars A
Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
Cancer research 2009;69(11):4708-15.
2009: Naumov George N; Nilsson Monique B; Cascone Tina; Briggs Alexandra; Straume Oddbjorn; Akslen Lars A; Lifshits Eugene; Byers Lauren Averett; Xu Li; Wu Hua-Kang; Jänne Pasi; Kobayashi Susumu; Halmos Balazs; Tenen Daniel; Tang Xi M; Engelman Jeffrey; Yeap Beow; Folkman Judah; Johnson Bruce E; Heymach John V
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3484-94.
2009: Rakha Emad A; Elsheikh Somaia E; Aleskandarany Muhammed A; Habashi Hany O; Green Andrew R; Powe Desmond G; El-Sayed Maysa E; Benhasouna Ahmed; Brunet Jean-Sébastien; Akslen Lars A; Evans Andy J; Blamey Roger; Reis-Filho Jorge S; Foulkes William D; Ellis Ian O
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2302-10.
2009: Pjanova Dace; Molven Anders; Akslen Lars A; Engele Ludmila; Streinerte Baiba; Azarjana Kristine; Heisele Olita
Identification of a CDK4 R24H mutation-positive melanoma family by analysis of early-onset melanoma patients in Latvia.
Melanoma research 2009;19(2):119-22.
2009: Salvesen H B; Carter S L; Mannelqvist M; Dutt A; Getz G; Stefansson I M; Raeder M B; Sos M L; Engelsen I B; Trovik J; Wik E; Greulich H; Bø T H; Jonassen I; Thomas R K; Zander T; Garraway L A; Oyan A M; Sellers W R; Kalland K H; Meyerson M; Akslen L A; Beroukhim R
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(12):4834-9.
2009: Etemadmoghadam Dariush; deFazio Anna; Beroukhim Rameen; Mermel Craig; George Joshy; Getz Gad; Tothill Richard; Okamoto Aikou; Raeder Maria B; Harnett Paul; Lade Stephen; Akslen Lars A; Tinker Anna V; Locandro Bianca; Alsop Kathryn; Chiew Yoke-Eng; Traficante Nadia; Fereday Sian; Johnson Daryl; Fox Stephen; Sellers William; Urashima Mitsuyoshi; Salvesen Helga B; Meyerson Matthew; Bowtell David;
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1417-27.
2009: Arnes J B; Bégin L R; Stefansson I; Brunet J-S; Nielsen T O; Foulkes W D; Akslen L A
Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Journal of clinical pathology 2009;62(2):139-46.
2009: Mannelqvist Monica; Stefansson Ingunn; Salvesen Helga B; Akslen Lars A
Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma.
Histopathology 2009;54(2):174-83.
2009: Moen Ingrid; Øyan Anne Margrete; Kalland Karl-Henning; Tronstad Karl Johan; Akslen Lars Andreas; Chekenya Martha; Sakariassen Per Øystein; Reed Rolf Kåre; Stuhr Linda Elin Birkhaug
Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model.
PloS one 2009;4(7):e6381.
2009: Ke Xi-Song; Qu Yi; Rostad Kari; Li Wen-Cheng; Lin Biaoyang; Halvorsen Ole Johan; Haukaas Svein A; Jonassen Inge; Petersen Kjell; Goldfinger Naomi; Rotter Varda; Akslen Lars A; Oyan Anne M; Kalland Karl-Henning
Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
PloS one 2009;4(3):e4687.
2008: Engelsen Ingeborg B; Stefansson Ingunn M; Akslen Lars A; Salvesen Helga B
GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
American journal of obstetrics and gynecology 2008;199(5):543.e1-7.
2008: Akslen Lars A; Naumov George N
Tumor dormancy--from basic mechanisms to clinical practice.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2008;116(7-8):545-7.
2008: Nalwoga Hawa; Arnes Jarle B; Wabinga Henry; Akslen Lars A
Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2008;116(6):515-25.
2008: Dutt Amit; Salvesen Helga B; Chen Tzu-Hsiu; Ramos Alex H; Onofrio Robert C; Hatton Charlie; Nicoletti Richard; Winckler Wendy; Grewal Rupinder; Hanna Megan; Wyhs Nicolas; Ziaugra Liuda; Richter Daniel J; Trovik Jone; Engelsen Ingeborg B; Stefansson Ingunn M; Fennell Tim; Cibulskis Kristian; Zody Michael C; Akslen Lars A; Gabriel Stacey; Wong Kwok-Kin; Sellers William R; Meyerson Matthew; Greulich Heidi
Drug-sensitive FGFR2 mutations in endometrial carcinoma.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(25):8713-7.
2008: Engelsen I B; Mannelqvist M; Stefansson I M; Carter S L; Beroukhim R; Øyan A M; Otte A P; Kalland K H; Akslen L A; Salvesen H B
Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma.
British journal of cancer 2008;98(10):1662-9.
2008: Bachmann Ingeborg M; Puntervoll Hanne E; Otte Arie P; Akslen Lars A
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2008;21(5):583-90.
2008: Lin Biaoyang; Utleg Angelita G; Gravdal Karsten; White James T; Halvorsen Ole J; Lu Wei; True Lawrence D; Vessella Robert; Lange Paul H; Nelson Peter S; Hood Leroy; Kalland Karl-Henning; Akslen Lars A
WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(5):1397-406.
2008: Borkamo Erling Dahl; Fluge Oystein; Mella Olav; Akslen Lars A; Bruland Ove; Dahl Olav
Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2008;86(3):435-42.
2008: Naumov George N; Heymach John; Akslen Lars A
Dr. Folkman's legacy-a life of angiogenesis research.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2008;116(2):89-92.
2008: Arnes J B; Collett K; Akslen L A
Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1.
Histopathology 2008;52(3):370-80.
2008: Akslen Lars A; Puntervoll Hanne; Bachmann Ingeborg M; Straume Oddbjørn; Vuhahula Edda; Kumar Rajiv; Molven Anders
Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.
Melanoma research 2008;18(1):29-35.
2008: Engelsen Ingeborg B; Stefansson Ingunn M; Beroukhim Rameen; Sellers William R; Meyerson Matthew; Akslen Lars A; Salvesen Helga B
HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.
International journal of oncology 2008;32(2):307-16.
2008: Helsing Per; Nymoen Dag Andre; Ariansen Sarah; Steine Solrun J; Maehle Lovise; Aamdal Steinar; Langmark Frøydis; Loeb Mitchell; Akslen Lars A; Molven Anders; Andresen Per Arne
Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
Genes, chromosomes & cancer 2008;47(2):175-84.
2008: Bachmann Ingeborg M; Ladstein Rita G; Straume Oddbjørn; Naumov George N; Akslen Lars A
Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas.
BMC cancer 2008;8():362.
2008: Ke Xi-Song; Qu Yi; Goldfinger Naomi; Rostad Kari; Hovland Randi; Akslen Lars A; Rotter Varda; Øyan Anne Margrete; Kalland Karl-Henning
Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation.
PloS one 2008;3(10):e3368.
2007: Nalwoga Hawa; Arnes Jarle B; Wabinga Henry; Akslen Lars A
Frequency of the basal-like phenotype in African breast cancer.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2007;115(12):1391-9.
2007: Gravdal Karsten; Halvorsen Ole J; Haukaas Svein A; Akslen Lars A
A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(23):7003-11.
2007: Petersen Kjell; Oyan Anne Margrete; Rostad Kari; Olsen Sue; Bø Trond Hellem; Salvesen Helga B; Gjertsen Bjørn Tore; Bruserud Oystein; Halvorsen Ole Johan; Akslen Lars Andreas; Steen Vidar M; Jonassen Inge; Kalland Karl-Henning
Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization.
Analytical biochemistry 2007;366(1):46-58.
2007: Halvorsen Ole Johan; Rostad Kari; Øyan Anne Margrete; Puntervoll Hanne; Bø Trond Hellem; Stordrange Laila; Olsen Sue; Haukaas Svein Andreas; Hood Leroy; Jonassen Inge; Kalland Karl-Henning; Akslen Lars Andreas
Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(3):892-7.
2007: Rostad Kari; Mannelqvist Monica; Halvorsen Ole Johan; Oyan Anne Margrete; Bø Trond Hellem; Stordrange Laila; Olsen Sue; Haukaas Svein Andreas; Lin Biaoyang; Hood Leroy; Jonassen Inge; Akslen Lars Andreas; Kalland Karl-Henning
ERG upregulation and related ETS transcription factors in prostate cancer.
International journal of oncology 2007;30(1):19-32.
2007: Tischkowitz Marc; Brunet Jean-Sébastien; Bégin Louis R; Huntsman David G; Cheang Maggie C U; Akslen Lars A; Nielsen Torsten O; Foulkes William D
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.
BMC cancer 2007;7():134.
2006: Sørlie Therese; Perou Charles M; Fan Cheng; Geisler Stephanie; Aas Turid; Nobel Andrew; Anker Gun; Akslen Lars A; Botstein David; Børresen-Dale Anne-Lise; Lønning Per Eystein
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer.
Molecular cancer therapeutics 2006;5(11):2914-8.
2006: Engelsen Ingeborg B; Stefansson Ingunn; Akslen Lars A; Salvesen Helga B
Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.
American journal of obstetrics and gynecology 2006;195(4):979-86.
2006: Naumov George N; Akslen Lars A; Folkman Judah
Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch.
Cell cycle (Georgetown, Tex.) 2006;5(16):1779-87.
2006: Almog Nava; Henke Vanessa; Flores Ludmila; Hlatky Lynn; Kung Andrew L; Wright Renee D; Berger Raanan; Hutchinson Lloyd; Naumov George N; Bender Elise; Akslen Lars A; Achilles Eike-Gert; Folkman Judah
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006;20(7):947-9.
2006: Stefansson Ingunn M; Salvesen Helga B; Akslen Lars A
Vascular proliferation is important for clinical progress of endometrial cancer.
Cancer research 2006;66(6):3303-9.
2006: Naumov George N; Bender Elise; Zurakowski David; Kang Soo-Young; Sampson David; Flynn Evelyn; Watnick Randolph S; Straume Oddbjorn; Akslen Lars A; Folkman Judah; Almog Nava
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype.
Journal of the National Cancer Institute 2006;98(5):316-25.
2006: Stefansson Ingunn M; Salvesen Helga B; Akslen Lars A
Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients.
International journal of cancer. Journal international du cancer 2006;118(5):1227-33.
2006: Fluge Øystein; Bruland Ove; Akslen Lars A; Lillehaug Johan R; Varhaug Jan E
Gene expression in poorly differentiated papillary thyroid carcinomas.
Thyroid : official journal of the American Thyroid Association 2006;16(2):161-75.
2006: Collett Karin; Eide Geir E; Arnes Jarle; Stefansson Ingunn M; Eide Johan; Braaten Audun; Aas Turid; Otte Ariel P; Akslen Lars A
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1168-74.
2006: Haukaas Svein A; Halvorsen Ole J; Daehlin Lars; Hostmark Jens; Akslen Lars A
Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
BJU international 2006;97(1):51-5.
2006: Bachmann Ingeborg M; Halvorsen Ole J; Collett Karin; Stefansson Ingunn M; Straume Oddbjørn; Haukaas Svein A; Salvesen Helga B; Otte Arie P; Akslen Lars A
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(2):268-73.
2006: Gravdal Karsten; Halvorsen Ole J; Haukaas Svein A; Akslen Lars A
Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer.
Virchows Archiv : an international journal of pathology 2006;448(1):68-74.
2005: Bachmann Ingeborg M; Straume Oddbjørn; Puntervoll Hanne E; Kalvenes May Britt; Akslen Lars A
Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8606-14.
2005: Straume O; Akslen L A
Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma.
British journal of cancer 2005;93(8):933-8.
2005: Molven Anders; Grimstvedt Magne B; Steine Solrun J; Harland Mark; Avril Marie-Françoise; Hayward Nicholas K; Akslen Lars A
A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation.
Genes, chromosomes & cancer 2005;44(1):10-8.
2005: Akslen Lars A; Angelini Sabrina; Straume Oddbjørn; Bachmann Ingeborg M; Molven Anders; Hemminki Kari; Kumar Rajiv
BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.
The Journal of investigative dermatology 2005;125(2):312-7.
2005: Salvesen Helga B; Kumar Rajiv; Stefansson Ingunn; Angelini Sabrina; MacDonald Nicola; Smeds Johanna; Jacobs Ian J; Hemminki Kari; Das Soma; Akslen Lars A
Low frequency of BRAF and CDKN2A mutations in endometrial cancer.
International journal of cancer. Journal international du cancer 2005;115(6):930-4.
2005: Arnes Jarle B; Brunet Jean-Sébastien; Stefansson Ingunn; Bégin Louis R; Wong Nora; Chappuis Pierre O; Akslen Lars A; Foulkes William D
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4003-11.
2005: Collett Karin; Stefansson Ingunn M; Eide Johan; Braaten Audun; Wang Hege; Eide Geir Egil; Thoresen Steinar Ø; Foulkes William D; Akslen Lars A
A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(5):1108-12.
2005: Aas Turid; Geisler Stephanie; Helle Hildegunn; Børresen-Dale Anne-Lise; Lønning Per Eystein; Akslen Lars Andreas
Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin.
Oncology reports 2005;13(3):525-30.
2005: Halvorsen Ole Johan; Oyan Anne Margrete; Bø Trond Hellem; Olsen Sue; Rostad Kari; Haukaas Svein Andreas; Bakke August Magnar; Marzolf Bruz; Dimitrov Krassen; Stordrange Laila; Lin Biaoyang; Jonassen Inge; Hood Leroy; Akslen Lars Andreas; Kalland Karl-Henning
Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.
International journal of oncology 2005;26(2):329-36.
2005: Gjengstø Peder; Paus Elisabeth; Halvorsen Ole Johan; Eide Johan; Akslen Lars Andreas; Wentzel-Larsen Tore; Hoisaeter Per Aage
Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study.
The Journal of urology 2005;173(2):425-8.
2005: Sharma Praveen; Sahni Narinder S; Tibshirani Robert; Skaane Per; Urdal Petter; Berghagen Hege; Jensen Marianne; Kristiansen Lena; Moen Cecilie; Sharma Pradeep; Zaka Alia; Arnes Jarle; Sauer Torill; Akslen Lars A; Schlichting Ellen; Børresen-Dale Anne-Lise; Lönneborg Anders
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells.
Breast cancer research : BCR 2005;7(5):R634-44.
2004: Salvesen Helga B; Stefansson Ingunn; Kretzschmar Ellen I; Gruber Paula; MacDonald Nicola D; Ryan Andy; Jacobs Ian J; Akslen Lars A; Das Soma
Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression.
International journal of oncology 2004;25(6):1615-23.
2004: Bachmann Ingeborg M; Straume Oddbjørn; Akslen Lars A
Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
International journal of oncology 2004;25(6):1559-65.
2004: Macdonald N D; Salvesen H B; Ryan A; Malatos S; Stefansson I; Iversen O E; Akslen L A; Das S; Jacobs I J
Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(5):957-65.
2004: Nielsen Torsten O; Hsu Forrest D; Jensen Kristin; Cheang Maggie; Karaca Gamze; Hu Zhiyuan; Hernandez-Boussard Tina; Livasy Chad; Cowan Dave; Dressler Lynn; Akslen Lars A; Ragaz Joseph; Gown Allen M; Gilks C Blake; van de Rijn Matt; Perou Charles M
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(16):5367-74.
2004: Eikesdal Hans Petter; Dahl Olav; Straume Oddbjørn; Akslen Lars A
[Tumour angiogenesis and therapy directed at the neovasculature]
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 2004;124(15):1919-22.
2004: Stefansson I M; Salvesen H B; Immervoll H; Akslen L A
Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type.
Histopathology 2004;44(5):472-9.
2004: Stefansson Ingunn M; Salvesen Helga B; Akslen Lars A
Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1242-52.
2004: Foulkes William D; Brunet Jean-Sébastien; Stefansson Ingunn M; Straume Oddbjørn; Chappuis Pierre O; Bégin Louis R; Hamel Nancy; Goffin John R; Wong Nora; Trudel Michel; Kapusta Linda; Porter Peggy; Akslen Lars A
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.
Cancer research 2004;64(3):830-5.
2003: Geisler Stephanie; Børresen-Dale Anne-Lise; Johnsen Hilde; Aas Turid; Geisler Jürgen; Akslen Lars Andreas; Anker Gun; Lønning Per Eystein
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5582-8.
2003: Salvesen Helga B; Gulluoglu Mine G; Stefansson Ingunn; Akslen Lars A
Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2003;111(11):1011-8.
2003: Halford Sarah E R; Sawyer Elinor J; Lambros Maryou B; Gorman Patricia; Macdonald Nicola D; Talbot Ian C; Foulkes William D; Gillett Cheryl E; Barnes Diana M; Akslen Lars A; Lee Kwok; Jacobs Ian J; Hanby Andrew M; Ganesan Trivadi S; Salvesen Helga B; Bodmer Walter F; Tomlinson Ian P M; Roylance Rebecca R
MSI-low, a real phenomenon which varies in frequency among cancer types.
The Journal of pathology 2003;201(3):389-94.
2003: Alexander-Sefre Farhad; Salvesen Helga B; Ryan Andy; Singh Naveena; Akslen Lars A; MacDonald Nicolla; Wilbanks George; Jacobs Ian J
Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis.
Gynecologic oncology 2003;91(1):218-25.
2003: Foulkes William D; Stefansson Ingunn M; Chappuis Pierre O; Bégin Louis R; Goffin John R; Wong Nora; Trudel Michel; Akslen Lars A
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
Journal of the National Cancer Institute 2003;95(19):1482-5.
2003: Goffin J R; Straume O; Chappuis P O; Brunet J-S; Bégin L R; Hamel N; Wong N; Akslen L A; Foulkes W D
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer.
British journal of cancer 2003;89(6):1031-4.
2003: Gjengstø Peder; Halvorsen Ole Johan; Akslen Lars Andreas; Frugård Jannicke; Hoisaeter Per Aage
Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded: a prospective study of 510 patients.
Urology 2003;62(3):447-50.
2003: Halvorsen Ole J; Haukaas Svein A; Akslen Lars A
Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1474-9.
2003: Aas T; Geisler S; Eide G E; Haugen D F; Varhaug J E; Bassøe A M; Thorsen T; Berntsen H; Børresen-Dale A L; Akslen L A; Lønning P E
Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.
European journal of cancer (Oxford, England : 1990) 2003;39(4):438-46.
2003: Straume Oddbjørn; Jackson David G; Akslen Lars A
Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):250-6.
2003: Straume Oddbjørn; Akslen Lars A
Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma.
Angiogenesis 2003;6(4):295-301.
2002: Straume Oddbjørn; Chappuis Pierre O; Salvesen Helga B; Halvorsen Ole J; Haukaas Svein A; Goffin John R; Bégin Louis R; Foulkes William D; Akslen Lars A
Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers.
Cancer research 2002;62(23):6808-11.
2002: Salvesen Helga B; Akslen Lars A
Molecular pathogenesis and prognostic factors in endometrial carcinoma.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2002;110(10):673-89.
2002: Paessler Michele; Kreisel Friederike H C; LiVolsi Virginia A; Akslen Lars A; Baloch Zubair W
Can we rely on pathologic parameters to define conservative treatment of papillary thyroid carcinoma?
International journal of surgical pathology 2002;10(4):267-72.
2002: Fluge Øystein; Bruland Ove; Akslen Lars A; Varhaug Jan E; Lillehaug Johan R
NATH, a novel gene overexpressed in papillary thyroid carcinomas.
Oncogene 2002;21(33):5056-68.
2002: Straume Oddbjørn; Smeds Johanna; Kumar Rajiv; Hemminki Kari; Akslen Lars Andreas
Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase.
The American journal of pathology 2002;161(1):229-37.
2002: Salvesen Helga B; Stefansson Ingunn; Kalvenes May Britt; Das Soma; Akslen Lars A
Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma.
Cancer 2002;94(8):2185-91.
2002: Straume Oddbjørn; Akslen Lars Andreas
Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression.
The American journal of pathology 2002;160(3):1009-19.
2002: Stefansson Ingunn; Akslen Lars A; MacDonald Nicola; Ryan Andy; Das Soma; Jacobs Ian J; Salvesen Helga B
Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):138-43.
2001: Halvorsen O J; Haukaas S; Høisaeter P A; Akslen L A
Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy.
Anticancer research 2001;21(6A):4071-6.
2001: Kumar R; Smeds J; Berggren P; Straume O; Rozell B L; Akslen L A; Hemminki K
A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.
International journal of cancer. Journal international du cancer 2001;95(6):388-93.
2001: Straume O; Akslen L A
Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.
The American journal of pathology 2001;159(1):223-35.
2001: Geisler S; Lønning P E; Aas T; Johnsen H; Fluge O; Haugen D F; Lillehaug J R; Akslen L A; Børresen-Dale A L
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Cancer research 2001;61(6):2505-12.
2001: Fluge O; Haugen D R; Akslen L A; Marstad A; Santoro M; Fusco A; Varhaug J E; Lillehaug J R
Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas.
Oncogene 2001;20(7):885-92.
2001: Frich L; Glattre E; Akslen L A
Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(2):113-7.
2001: Salvesen H B; MacDonald N; Ryan A; Jacobs I J; Lynch E D; Akslen L A; Das S
PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma.
International journal of cancer. Journal international du cancer 2001;91(1):22-6.
2000: Vuhahula E; Straume O; Akslen L A
Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans.
Anticancer research 2000;20(6C):4857-62.
2000: Halvorsen O J; Haukaas S; Høisaeter P A; Akslen L A
Independent prognostic importance of microvessel density in clinically localized prostate cancer.
Anticancer research 2000;20(5C):3791-9.
2000: Salvesen H B; MacDonald N; Ryan A; Iversen O E; Jacobs I J; Akslen L A; Das S
Methylation of hMLH1 in a population-based series of endometrial carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3607-13.
2000: Fluge O; Akslen L A; Haugen D R; Varhaug J E; Lillehaug J R
Expression of heregulins and associations with the ErbB family of tyrosine kinase receptors in papillary thyroid carcinomas.
International journal of cancer. Journal international du cancer 2000;87(6):763-70.
2000: Perou C M; Sørlie T; Eisen M B; van de Rijn M; Jeffrey S S; Rees C A; Pollack J R; Ross D T; Johnsen H; Akslen L A; Fluge O; Pergamenschikov A; Williams C; Zhu S X; Lønning P E; Børresen-Dale A L; Brown P O; Botstein D
Molecular portraits of human breast tumours.
Nature 2000;406(6797):747-52.
2000: Straume O; Sviland L; Akslen L A
Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1845-53.
2000: Akslen L A; LiVolsi V A
Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma.
Cancer 2000;88(8):1902-8.
2000: MacDonald N D; Salvesen H B; Ryan A; Iversen O E; Akslen L A; Jacobs I J
Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas.
Cancer research 2000;60(6):1750-2.
2000: Salvesen H B; Das S; Akslen L A
Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):153-9.
2000: Halvorsen O J; Høstmark J; Haukaas S; Høisaeter P A; Akslen L A
Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma.
Cancer 2000;88(2):416-24.
1999: Haugen D R; Lillehaug J R; Akslen L A
Enhanced expression of EGF receptor and low frequency of ras mutations in X-ray-induced rat thyroid tumours.
Virchows Archiv : an international journal of pathology 1999;435(4):434-41.
1999: Salvesen H B; Akslen L A
Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
International journal of cancer. Journal international du cancer 1999;84(5):538-43.
1999: Straume O; Salvesen H B; Akslen L A
Angiogenesis is prognostically important in vertical growth phase melanomas.
International journal of oncology 1999;15(3):595-9.
1999: Salvesen H B; Iversen O E; Akslen L A
Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1382-90.
1998: Frich L; Akslen L A; Glattre E
[Increased incidence of thyroid cancer among Norwegian women married to fishermen]
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 1998;118(27):4202-5.
1998: Salvesen H B; Iversen O E; Akslen L A
Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2779-85.
1998: Salvesen H B; Iversen O E; Akslen L A
Prognostic impact of morphometric nuclear grade of endometrial carcinoma.
Cancer 1998;83(5):956-64.
1998: Heuch J M; Heuch I; Akslen L A; Kvåle G
Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study.
International journal of cancer. Journal international du cancer 1998;77(4):498-503.
1998: Akslen L A; Sothern R B
Seasonal variations in the presentation and growth of thyroid cancer.
British journal of cancer 1998;77(7):1174-9.
1998: Salvesen H B; Iversen O E; Akslen L A
Independent prognostic importance of microvessel density in endometrial carcinoma.
British journal of cancer 1998;77(7):1140-4.
1998: Salvesen H B; Akslen L A; Albrektsen G; Iversen O E
Poorer survival of nulliparous women with endometrial carcinoma.
Cancer 1998;82(7):1328-33.
1998: Akslen L A; Monstad S E; Larsen B; Straume O; Ogreid D
Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type.
International journal of cancer. Journal international du cancer 1998;79(1):91-5.
1997: Straume O; Akslen L A
Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma.
International journal of cancer. Journal international du cancer 1997;74(5):535-9.
1997: Akslen L A
[With the microscope as weapon. A comment to criminal novels by Patricia D. Cornwell]
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 1997;117(8):1149-52.
1997: Paulsen T; Aas T; Børresen A L; Varhaug J E; Lønning P E; Akslen L A
Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer.
International journal of cancer. Journal international du cancer 1997;74(1):138-40.
1997: Ellis P A; Lonning P E; Borresen-Dale A; Aas T; Geisler S; Akslen L A; Salter I; Smith I E; Dowsett M
Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.
British journal of cancer 1997;76(4):480-5.
1997: Frich L; Akslen L A; Glattre E
Increased risk of thyroid cancer among Norwegian women married to fishery workers--a retrospective cohort study.
British journal of cancer 1997;76(3):385-9.
1996: Akslen L A; Maehle B O; Varhaug J E
Aggressive thyroid carcinoma with predominant cribriform growth pattern. Case report.
Pathology, research and practice 1996;192(11):1129-33; discussion 1134.
1996: Straume O; Akslen L A
Independent prognostic importance of vascular invasion in nodular melanomas.
Cancer 1996;78(6):1211-9.
1996: Haugen D R; Akslen L A; Varhaug J E; Lillehaug J R
Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas.
Cancer research 1996;56(6):1184-8.
1996: Ness G O; Haugen D R; Varhaug J E; Akslen L A; Lillehaug J R
Cytoplasmic localization of EGF receptor in papillary thyroid carcinomas: association with the 150-kDa receptor form.
International journal of cancer. Journal international du cancer 1996;65(2):161-7.
1995: Akslen L A; Varhaug J E
Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Cancer 1995;76(9):1643-54.
1994: Akslen L A
[Etiological and pathological aspects of malignant melanoma]
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 1994;114(8):908-11.
1993: Akslen L A
Prognostic importance of histologic grading in papillary thyroid carcinoma.
Cancer 1993;72(9):2680-5.
1993: Akslen L A; Myking A O; Salvesen H; Varhaug J E
Prognostic impact of EGF-receptor in papillary thyroid carcinoma.
British journal of cancer 1993;68(4):808-12.
1993: Haugen D R; Akslen L A; Varhaug J E; Lillehaug J R
Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas.
International journal of cancer. Journal international du cancer 1993;55(1):37-43.
1993: Akslen L A; Haldorsen T; Thoresen S O; Glattre E
Incidence pattern of thyroid cancer in Norway: influence of birth cohort and time period.
International journal of cancer. Journal international du cancer 1993;53(2):183-7.
1992: Salvesen H; Njølstad P R; Akslen L A; Albrektsen G; Søreide O; Varhaug J E
Papillary thyroid carcinoma: a multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system.
The European journal of surgery = Acta chirurgica 1992;158(11-12):583-9.
1992: Akslen L A; Mørkve O
Expression of p53 protein in cutaneous melanoma.
International journal of cancer. Journal international du cancer 1992;52(1):13-6.
1992: Haugen D R; Akslen L A; Varhaug J E; Lillehaug J R
Expression of c-erbB-2 protein in papillary thyroid carcinomas.
British journal of cancer 1992;65(6):832-7.
1992: Akslen L A; Nilssen S; Kvåle G
Reproductive factors and risk of thyroid cancer. A prospective study of 63,090 women from Norway.
British journal of cancer 1992;65(5):772-4.
1992: Akslen L A; Myking A O
Differentiated thyroid carcinomas: the relevance of various pathological features for tumour classification and prediction of tumour progress.
Virchows Archiv. A, Pathological anatomy and histopathology 1992;421(1):17-23.
1992: Akslen L A; Glattre E
Second malignancies in thyroid cancer patients: a population-based survey of 3658 cases from Norway.
European journal of cancer (Oxford, England : 1990) 1992;28(2-3):491-5.
1992: Akslen L A; Myking A O; Salvesen H; Varhaug J E
Prognostic importance of various clinicopathological features in papillary thyroid carcinoma.
European journal of cancer (Oxford, England : 1990) 1992;29A(1):44-51.
1991: Salvesen H; Njølstad P R; Akslen L A; Albrektsen G; Viste A; Søreide O; Varhaug J E
Thyroid carcinoma: results from surgical treatment in 211 consecutive patients.
The European journal of surgery = Acta chirurgica 1991;157(9):521-6.
1991: Akslen L A; Haldorsen T; Thoresen S O; Glattre E
Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway.
Cancer research 1991;51(4):1234-41.
1991: Smaaland R; Akslen L A; Tønder B; Mehus A; Lote K; Albrektsen G
Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients.
British journal of urology 1991;67(1):61-9.
1990: Akslen L A; Myking A O; Mørkve O; Gulsvik A; Raithel H J; Schaller K H
Increased content of chromium and nickel in lung tissues from patients with bronchial carcinoma.
Pathology, research and practice 1990;186(6):717-22.
1990: Aasland R; Akslen L A; Varhaug J E; Lillehaug J R
Co-expression of the genes encoding transforming growth factor-alpha and its receptor in papillary carcinomas of the thyroid.
International journal of cancer. Journal international du cancer 1990;46(3):382-7.
1990: Akslen L A; Haldorsen T; Thoresen S O; Glattre E
Incidence of thyroid cancer in Norway 1970-1985. Population review on time trend, sex, age, histological type and tumour stage in 2625 cases.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 1990;98(6):549-58.
1990: Glattre E; Hostmark A; Thoresen S O; Smith A J; Akslen L A
Provocation of thyroid neoplasms in female Wistar rats fed n-3 or n-6 fatty acids in the feed.
Thyroidology / A.P.R.I.M 1990;2(1):1-3.
1990: Glattre E; Akslen L A; Thoresen S O; Haldoren T
Geographic patterns and trends in the incidence of thyroid cancer in Norway 1970-1986.
Cancer detection and prevention 1990;14(6):625-31.
1989: Akslen L A; Myking A O
Balloon cell melanoma mimicking clear cell carcinoma.
Pathology, research and practice 1989;184(5):548-50; discussion 551-3.
1989: Thoresen S O; Akslen L A; Glattre E; Haldorsen T; Lund E V; Schoultz M
Survival and prognostic factors in differentiated thyroid cancer--a multivariate analysis of 1,055 cases.
British journal of cancer 1989;59(2):231-5.
1989: Raithel H J; Schaller K H; Akslen L A; Myking A O; Mørkve O; Gulsvik A
Analyses of chromium and nickel in human pulmonary tissue. Investigations in lung cancer patients and a control population under special consideration of medical expertise aspects.
International archives of occupational and environmental health 1989;61(8):507-12.
1988: Akslen L A; Hartveit F
Metastatic melanoma of unknown origin at autopsy.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1988;14(5):379-82.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Lars Akslen

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Physiology

Devices

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Lars Akslen (preview)

All Publications